📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3 — Appendices & Regional (3.2.A/3.2.R) (TILA-278)

Document ID: M3-AR
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4Q; Q3D

Appendices & Regional Information (3.2.A / 3.2.R) — TILA-278

This section provides the CTD appendices (3.2.A) and the region-specific information (3.2.R) supporting the marketing application for TILA-278, a recombinant humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody — one arm a neutralizing antagonist of TL1A (TNFSF15), the second arm an agonist of the interleukin-22 receptor (IL-22RA1/IL-10RB) — expressed in Chinese hamster ovary (CHO) cells and presented as a sterile, preservative-free subcutaneous (SC) solution in a single-use prefilled syringe (PFS) and a PFS-based autoinjector for moderate-to-severe ulcerative colitis (UC). The content is prepared in accordance with ICH M4Q(R1) and, for the adventitious-agent and viral-safety elements, with ICH Q5A(R2), Q5B, and Q5D; the elemental-impurity risk assessment follows ICH Q3D. The information is consistent with, and cross-referenced to, the drug-substance dossier (3.2.S), the drug-product dossier (3.2.P), and the integrated control-strategy document (3.2 Control Strategy and Specifications). In the United States the application is a Biologics License Application submitted under 21 CFR Part 601; because the presentation is a drug-device combination product, the device constituent is governed additionally by 21 CFR Part 4.

3.2.A Appendices

The appendices address facilities and equipment (GMP status of the manufacturing, testing, and release sites), adventitious-agents safety (cell-line history, non-viral and viral safety, and viral-clearance validation), and novel excipients — of which there are none in the TILA-278 formulation, as detailed in 3.2.A.3.

3.2.A.1 Facilities and Equipment

The drug substance (DS) is manufactured, tested, and released by Virtual Biopharma Inc. (or its named contract manufacturing organization); the drug product (DP) is filled and finished, and the PFS/autoinjector combination product is assembled, labeled, and packaged, at the sites listed in the facilities table. For each site the appendix provides the name, full address, DUNS/FEI identifier, the manufacturing operations performed, and the current GMP compliance and inspection status; valid manufacturing authorizations and the establishment information are cross-referenced in Module 1 (Regional Administrative Information).

The DS facility is a multiproduct biopharmaceutical operation in which TILA-278 is produced by fed-batch mammalian cell culture at a nominal commercial scale of a 2000 L single-use production bioreactor (SUB), followed by a platform downstream train (Protein A affinity capture, orthogonal polishing chromatography, dedicated low-pH viral inactivation and 20 nm virus-retentive nanofiltration, and ultrafiltration/diafiltration [UF/DF]). To control the risk of cross-contamination and mix-up inherent to concurrent multiproduct operation, the facility relies on:

• Closed and single-use processing — predominantly single-use bioreactors, mixers, tubing, and product-contact assemblies, together with closed or functionally closed transfer operations, minimizing open handling and shared product-contact surfaces.
• Spatial and temporal segregation — unidirectional flows for personnel, materials, product, and waste; classified environments appropriate to each operation (culminating in Grade A/ISO 5 aseptic processing for the sterile DP fill); campaign-based operation with validated changeover and cleaning between products where shared equipment or suites are used.
• Cleaning and changeover validation — for any product-contact equipment that is not single-use, cleaning validation establishes carryover limits (including a health-based, ADE/PDE-derived acceptance criterion) and confirms removal of product, cleaning agents, and bioburden; single-use assemblies are used once and discarded, eliminating carryover at those steps.
• Environmental and utility control — qualified HVAC, water-for-injection (WFI) and clean-steam systems, and an environmental-monitoring program commensurate with the classification of each area.

Process-flow, personnel-flow, material-flow, and waste-flow diagrams, together with the equipment inventory and the assessment of concurrent (adjacent) operations that could bear on adventitious-agent segregation, are provided to allow the reviewer to assess containment and segregation. The facility operates under the pharmaceutical quality system described under ICH Q10 and is maintained in a state of inspection readiness.

3.2.A.2 Adventitious Agents Safety Evaluation

Adventitious-agent safety for TILA-278 is assured by the complementary strategy of ICH Q5A(R2): (i) selection and characterization of the cell substrate and raw materials; (ii) testing of the unprocessed bulk (and defined in-process stages) for adventitious agents; and (iii) validated capacity of the purification process to inactivate and remove potential viral contaminants. Non-viral adventitious agents (bacteria, fungi, mycoplasma, endotoxin, and transmissible spongiform encephalopathy [TSE] agents) are addressed alongside the viral evaluation.

Non-viral agents and TSE/BSE. The cell-culture media and feeds are chemically defined and animal-component-free, and the manufacturing process uses no materials of human or animal origin in routine production. Where any ancillary material of biological origin is used, it complies with the Note for Guidance on minimizing the risk of transmitting TSE agents (EMA/410/01 rev. 3) and Ph. Eur. 5.2.8; a TSE/BSE statement and the supporting certification are provided. Bacterial and fungal bioburden, mycoplasma, and bacterial endotoxin are controlled by defined in-process limits and by DS/DP release testing.

Cell substrate. TILA-278 is expressed in a CHO-K1-derived, glutamine-synthetase (GS)-selected host cell line. A two-tiered cell bank — master cell bank (MCB) and working cell bank (WCB) — has been established and characterized per ICH Q5A(R2), Q5B, and Q5D, including identity (isoenzyme/genetic), viability, sterility, mycoplasma, in vitro and in vivo adventitious-virus assays, and, for retroviruses, transmission electron microscopy (TEM) for endogenous retrovirus-like particles together with reverse-transcriptase (RT)/infectivity assays. As is characteristic of CHO cells, non-infectious endogenous retrovirus-like (Type C) particles are present; the cell substrate is otherwise free of detectable adventitious virus. Genetic stability of the coding sequence, copy number, and expression construct has been demonstrated from the MCB through and beyond the limit of in vitro cell age (LIVCA) used for production. Consistent with the risk-based emphasis of ICH Q5A(R2), broad, sequence-agnostic detection by next-generation sequencing (NGS) has been applied as an orthogonal complement to the in vitro assays for cell-substrate and unprocessed-bulk evaluation.

Testing of unprocessed bulk and in-process material. Each unprocessed bulk harvest (clarified, pre-Protein A) is tested for adventitious virus by in vitro assays on indicator cell lines, for mycoplasma, and for bioburden; endotoxin and bioburden are controlled at defined downstream stages. Release of the harvest for further processing is contingent on conformance of these adventitious-agent controls.

Viral clearance validation. The capacity of the purification process to clear virus was evaluated in a scaled-down, qualified model per ICH Q5A(R2), using a panel of a relevant retrovirus model and specific model viruses spanning enveloped/non-enveloped and RNA/DNA genomes and a range of physicochemical resistance. Clearance credit is taken across orthogonal mechanisms: enveloped-virus inactivation by low-pH hold of the Protein A eluate (pH ~3.5, ≥60 min), charge-based removal by anion-exchange chromatography (AEX, flow-through), and robust size-based removal by 20 nm virus-retentive nanofiltration. The representative cumulative log10 reduction values (LRV) — reproduced here from the drug-substance evaluation (3.2.S.2.5), where the full study design, spiking levels, and step-wise data are presented — are:

Process step	X-MuLV (enveloped, RNA)	PRV (enveloped, DNA)	MVM/MMV (non-enveloped, DNA)	Reo-3 (non-enveloped, RNA)
Low-pH inactivation	≥ 4.8	≥ 4.5	n/a	n/a
AEX (flow-through)	≥ 4.2	≥ 4.0	≥ 3.5	≥ 4.0
Nanofiltration (20 nm)	≥ 5.5	≥ 5.3	≥ 4.8	≥ 5.0
Cumulative LRV	≥ 14.5	≥ 13.8	≥ 8.3	≥ 9.0

Consistent with the known resistance of small non-enveloped parvoviruses to low pH, no inactivation credit is claimed for MVM/MMV or Reo-3 at the low-pH step; clearance of these agents is achieved by the orthogonal size- and charge-based removal steps. Combining a conservative estimate of the endogenous retrovirus-like particle load in the unprocessed bulk (quantified by TEM) with the validated cumulative retrovirus clearance of ≥ 14.5 log10 (X-MuLV, the relevant model for the CHO Type-C particle) yields a theoretical particle burden per maximum clinical dose far below one particle — a safety margin of many orders of magnitude — supporting the conclusion that the process provides a high assurance of retroviral safety. Facility- and process-level adventitious-agent segregation is described in 3.2.A.1.

3.2.A.3 Novel Excipients

TILA-278 drug product contains no novel excipient. The formulation comprises a histidine-based buffer system, a stabilizer/tonicity agent, and polysorbate as surfactant — all of which are pharmacopoeial (Ph. Eur./USP) or otherwise of well-established use in approved parenteral biologics at or below the concentrations employed. Accordingly, no full novel-excipient safety and quality package under 3.2.A.3 is required; the identity, specifications, and control of each excipient are provided in 3.2.P.4.

3.2.R Regional

The region-specific information — presented here for the United States BLA, with equivalent content prepared for other regions as applicable — comprises executed-batch and comparability information, the container-closure and, for the device presentation, the medical-device/combination-product particulars, an elemental-impurities risk assessment (ICH Q3D), and a nitrosamine risk assessment.

3.2.R.1 Executed Batch Records and Production Documentation

Representative executed batch records are provided for both the drug substance and the drug product, including the specific lots used to manufacture the clinical DP administered in the pivotal Phase 2b induction study TILA278-201 and the process-performance-qualification (PPQ) lots. Each executed record demonstrates conformance to the corresponding master batch record, documents the in-process control results against their acceptance limits, and captures the validated in-process hold times and storage conditions. The batch-numbering convention and the relationship between master and executed documentation are described so that reviewers can trace lot genealogy from cell-bank vial through DS, DP, and the assembled combination product.

3.2.R.2 Comparability Protocols and Post-Approval Change Management

Manufacturing changes across the product lifecycle are assessed for impact on critical quality attributes under an ICH Q5E comparability framework, supported by the release panel and extended physicochemical/functional characterization (higher-order structure, full glycan and charge-variant mapping, both potency bioassays, and correct-heterodimer/mispairing analysis). One or more post-approval change-management protocols (comparability protocols) are proposed to pre-define, for specified prospective changes, the tests, acceptance criteria, and reporting category, consistent with the lifecycle and established-conditions principles of ICH Q12. These protocols preserve continuity of the reportable quality result — in particular the dual-mechanism potency that links product quality to the dose-ordered efficacy observed in TILA278-201.

3.2.R.3 Container-Closure System and Combination-Product Information

The drug product is presented in a single-use prefilled syringe and in a PFS-based autoinjector incorporating the same primary container; full container-closure descriptions, materials of construction, compatibility, extractables/leachables, and container-closure integrity data reside in 3.2.P.2 and 3.2.P.7. Because the presentation is a drug-device combination product, the regional information additionally addresses the device constituent under 21 CFR Part 4:

• Design controls (21 CFR 820.30 / ISO 13485). The device constituent is developed under a design-control system; the design history file, design inputs/outputs, design verification and design validation, and risk management (ISO 14971) are summarized, with the essential performance requirements and their verification identified.
• Human factors / usability engineering. A human-factors program (IEC 62366-1 and the FDA human-factors guidance) — including use-related risk analysis, formative studies, and a validation (summative) usability study in representative users under actual or simulated use — supports safe and effective self-administration or caregiver administration by the intended UC population, including users with potential dexterity or visual limitations.
• Biocompatibility. Biological evaluation of patient-contacting materials follows ISO 10993-1, appropriate to a limited-duration parenteral contact.
• Essential device performance. Delivery performance is characterized and controlled at DP release and on stability, including break-loose and glide force, injection/delivery time for the autoinjector, activation force, dose accuracy/deliverable volume, and, for the PFS, needle-safety-system function; the acceptance criteria are given in 3.2.P.5.

Container-closure integrity is demonstrated by a validated physical method and is retained on stability in lieu of routine sterility testing.

3.2.R.4 Elemental Impurities Risk Assessment (ICH Q3D)

A risk assessment for elemental impurities has been performed in accordance with ICH Q3D for the parenteral route of administration. All potential sources were evaluated — the drug substance, each excipient, water (WFI), the manufacturing equipment (predominantly single-use polymeric product-contact materials, with any product-contact stainless-steel surfaces considered), and the primary container-closure/device components in contact with the solution. The assessment addressed the elements in ICH Q3D Classes 1, 2A, 2B, and 3 against the parenteral permitted daily exposures (PDE), taking account of the maximum clinical dose and the low intrinsic elemental content of a recombinant protein produced in chemically defined medium. The estimated total contribution for each element is below the control threshold (30% of the parenteral PDE); consequently, routine elemental-impurity testing at DS or DP release is not warranted, and control is assured by the risk assessment and by the qualified sourcing and specifications of the contributing materials.

3.2.R.5 Nitrosamine Risk Assessment

A nitrosamine risk assessment has been conducted following the applicable health-authority guidance. TILA-278 is a recombinant protein produced by mammalian cell culture and purified by chromatographic and filtration operations under aqueous, near-neutral to mildly acidic conditions; the active substance contains no small-molecule secondary or tertiary amine susceptible to N-nitrosation, so nitrosamine drug-substance-related impurities (NDSRIs) are not applicable to the active. The evaluation considered potential nitrosating conditions and the possible introduction of nitrite/nitrosating species via excipients (including trace nitrite associated with polysorbate) and process inputs, together with the container-closure and manufacturing materials. No combination of a vulnerable amine and a nitrosating agent under formation-favoring conditions was identified, and no root cause for N-nitrosamine formation is present in this process, formulation, or packaging. On this basis, confirmatory nitrosamine testing is not required; the assessment is maintained under the pharmaceutical quality system and will be revisited upon relevant changes to materials, process, or packaging.

3.2.R.6 Other Regional Information

Region-specific supporting content — including the full analytical method-validation reports, the TSE/BSE certification referenced in 3.2.A.2, and any additional administrative or labeling cross-references — is provided or cross-referenced as required by the receiving authority. The overall quality dossier, including these appendices and regional sections, is prepared consistent with ICH M4Q; Q3D; Q5A(R2); Q5C; and Q6B.

---

Cross-references: manufacturing facilities and equipment (3.2.A.1); adventitious-agent and viral safety (3.2.A.2; validated clearance detailed in 3.2.S.2.5); excipients (3.2.P.4); container-closure, device performance, and extractables/leachables (3.2.P.2, 3.2.P.5, 3.2.P.7); comparability and lifecycle management (3.2.S.2.6; control-strategy §8.5); specifications and clinical qualification against TILA278-201 (3.2.S.4, 3.2.P.5).